Page last updated: 2024-09-03

reboxetine and risperidone

reboxetine has been researched along with risperidone in 3 studies

Compound Research Comparison

Studies
(reboxetine)
Trials
(reboxetine)
Recent Studies (post-2010)
(reboxetine)
Studies
(risperidone)
Trials
(risperidone)
Recent Studies (post-2010) (risperidone)
6261931846,9241,5052,477

Protein Interaction Comparison

ProteinTaxonomyreboxetine (IC50)risperidone (IC50)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.015
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)0.0027
Alpha-2A adrenergic receptorHomo sapiens (human)0.0097
Cytochrome P450 2D6Homo sapiens (human)5.2734
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)4.1901
D(2) dopamine receptorHomo sapiens (human)0.0167
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)0.0991
Alpha-2B adrenergic receptorHomo sapiens (human)0.026
Alpha-2C adrenergic receptorHomo sapiens (human)0.0096
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)0.799
D(1A) dopamine receptorHomo sapiens (human)0.479
Histamine H2 receptorHomo sapiens (human)1.483
Alpha-1D adrenergic receptorHomo sapiens (human)0.01
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.0016
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.0057
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)0.799
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)0.0027
5-hydroxytryptamine receptor 2C Mus musculus (house mouse)0.0015
Alpha-1A adrenergic receptorHomo sapiens (human)0.0105
5-hydroxytryptamine receptor 2AMus musculus (house mouse)0.0015
Histamine H1 receptorHomo sapiens (human)0.4515
D(3) dopamine receptorHomo sapiens (human)0.024
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.023
D(2) dopamine receptorMus musculus (house mouse)0.023
D(2) dopamine receptorRattus norvegicus (Norway rat)0.0154
5-hydroxytryptamine receptor 2BMus musculus (house mouse)0.0015
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.6303
5-hydroxytryptamine receptor 1AMus musculus (house mouse)0.43
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)4.1901
Multidrug and toxin extrusion protein 1Homo sapiens (human)1.6

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ancione, M; Avenoso, A; Levita, A; Madia, A; Scordo, MG; Spina, E1
Baghai, TC; Laenger, A; Leicht, G; Lindhaus, S; Rupprecht, R; Schule, C1
Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J1

Trials

1 trial(s) available for reboxetine and risperidone

ArticleYear
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:6

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Citalopram; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Olanzapine; Psychiatric Status Rating Scales; Reboxetine; Risperidone; Schizophrenia; Schizophrenic Psychology

2014

Other Studies

2 other study(ies) available for reboxetine and risperidone

ArticleYear
No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites.
    Therapeutic drug monitoring, 2001, Volume: 23, Issue:6

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Clozapine; Drug Interactions; Female; Humans; Male; Middle Aged; Morpholines; Reboxetine; Risperidone

2001
Electroconvulsive therapy in a patient with concomitant depression and charcot-marie-tooth disease.
    The American journal of psychiatry, 2008, Volume: 165, Issue:6

    Topics: Aged; Charcot-Marie-Tooth Disease; Combined Modality Therapy; Comorbidity; Contraindications; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Male; Morpholines; Personality Inventory; Reboxetine; Risperidone; Treatment Outcome

2008